Introduction: despite initial dramatic efficacy of EGFR tyrosine kinase inhibitors (TKIs) in
EGFR-mutant lung cancer patients, emergence of acquired resistance is almost inevitable …

The tyrosine kinase inhibitors (TKIs) directed at sensitizing mutations in the epidermal
growth factor receptor (EGFR) gene represents a critical pillar in non-small cell lung cancer …

The treatment of lung cancer has changed dramatically with the development of tyrosine
kinase inhibitors (TKIs) that target sensitizing somatic mutations of the epidermal growth …

The discovery of activating mutations in the epidermal growth factor receptor (EGFR) gene
and the development of EGFR tyrosine kinase inhibitors (TKIs) have led to a paradigm shift …

The discovery of activating mutations in epidermal growth factor receptor (EGFR) in non-
small-cell lung cancer transformed the care and prognosis of patients and heralded the era …

Sensitizing mutations in the epidermal growth factor receptor (EGFR) predict response to
EGFR tyrosine kinase inhibitors (TKIs) and both first-and second-generation TKIs are …

According to global cancer data, lung cancer was the leading cause of cancer‑related death
in 2020. With the diversification of treatment strategies, the survival outcomes of patients with …

Tumours with sensitizing mutations in the EGFR gene constitute a distinct molecular
subgroup of non-small-cell lung cancers (NSCLCS) that benefit from precision medicine …

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have significantly
improved the survival of patients with advanced non-small cell lung cancer (NSCLC) …

In non-small cell lung cancer (NSCLC), the identification of epidermal growth factor receptor
(EGFR) mutations and the parallel development of EGFR tyrosine kinase inhibitors (TKIs) …